Currently, CAR-T cell therapy and immune checkpoint inhibitors targeting the PD-1/PD-L1 (programed cell death protein 1/programed cell death ligand 1) pathway have been successful in the clinical treatment of T-cell-centered tumor immunity [2–4]. This evidence concerns the gene PDCD1 and neoplasm.